Answers are grounded in this paper and cite their sources.
Background Cisplatin-based chemoradiotherapy (CRT) is standard for locally advanced head and neck squamous cell carcinoma (HNSCC), but the optimal initial cisplatin dose for elderly patients remains unclear.Aims/objectives To investigate the association between initial cisplatin dose, toxicity, and prognosis in elderly patients with HNSCC.Material and methods We retrospectively reviewed 58 patients with HNSCC treated with definitive CRT using triweekly cisplatin at 100 mg/m2 (high-dose) or 80 mg/m2 (low-dose). Outcomes were compared between groups, including age-based subgroup analyses.Results Overall survival was poorer in the high-dose group (p < 0.05). Among elderly patients, severe toxicity occurred in 35.7% and 9.1% of the high- and low-dose groups, respectively. Among elderly patients with recurrence, severe toxicity occurred in 4/4 and 1/8 patients, respectively (p < 0.05). The high-dose group also showed greater declines in body weight and body mass index during and poorer survival after second-line treatment (p < 0.01). Advanced disease and higher modified Glasgow Prognostic Score were associated with severe toxicity (p < 0.05).Conclusions and significance Higher initial cisplatin doses were associated with greater toxicity and poorer survival in elderly patients. Pretreatment nutritional and inflammatory status may help guide cisplatin dose selection.
No takes yet. Share an insight, caveat, or question.
Okuda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: